Featured Article

Where is RBQM Heading in The Future With AI?

Richard Young, Chief Strategy Officer at CluePoints, shares insights on AI and risk-based quality management (RBQM) in clinical trials. With experience at both CluePoints and Veeva, Young discusses AI’s role, transparency, and the future of risk management in clinical trials.

Guide

A Comprehensive Guide to Adaptive Site Monitoring

Download
Blog
RBQM for the Mid-Market Explained
  • Mid-market sponsors are expected to meet the same ICH E6(R3) standards as large pharma, often with...
Read More
Blog
5 Myths Mid-Market Teams Believe About RBQM and What ICH E6(R3) Actually Requires
  • Risk-Based Quality Management (RBQM) is no longer a future-state concept. Under ICH E6(R3), it is a...
Read More
Blog
Modern RBQM Has Evolved. Is Your Organization Ready?
  • Most sponsors and CROs are now fluent in the language of Risk-Based Quality Management (RBQM). Terms...
Read More
CluePoints RBQM Live25 On-Demand Recordings are now Available! Banner - ROI of RBQM, ICH E6(R3) in Practice, Future of AI